According to the latest report by IMARC Group, titled "Immunotherapy Drugs Market by Type (Monoclonal Antibodies, Vaccines, Interferons Alpha and Beta, Interleukins), Therapy Area (Cancer, Autoimmune and Inflammatory Diseases, Infectious Diseases, and Others), End User (Hospitals, Clinics, and Others), and Region 2023-2028," the global immunotherapy drugs market size reached US$ 195.4 Billion in 2022. Immunotherapy drugs refer to specialized medications used for treating a range of conditions, including lymphoma, melanoma, sarcoma, and lung, bladder, kidney, and breast cancer. These drugs stimulate the body's natural defenses by targeting and activating specific immune cells, such as T-cells, triggering an immunological response that aids in generating antibodies that prevent the growth of cancer cells. They also help fight against allergies and infections caused by bacteria and viruses. Some of the standard immunotherapy drugs available in the market include checkpoint inhibitors, monoclonal antibodies, and cancer vaccines. They provide long-lasting and sometimes permanent responses with fewer side effects than traditional chemotherapy and radiation treatments. As a result, immunotherapy drugs are becoming widely accepted and popular across the globe.
Global Immunotherapy Drugs Market Trends:
The widespread prevalence of cancer, tumor, and target diseases and the expanding geriatric population are primarily driving the global immunotherapy drugs market growth. Besides this, the rising incidences of genetic and lifestyle diseases due to the adoption of sedentary lifestyles and hectic schedules are supporting the market growth. Moreover, the shifting consumer preference for immunotherapy drugs that can be customized based on the patient's genetic profile and tailored to their individual needs to improve treatment outcomes is acting as another significant growth-inducing factor. Additionally, the enhancing popularity of antibodies and biosimilar drugs, the rise in the number of hospitals, pharmacies, and research laboratories, and extensive investments in research and development (R&D) activities to enhance the formulation of immunotherapy drugs are creating a favorable outlook for the market. Furthermore, the escalating focus on strategic collaborations and new product developments by key market players to expand their product portfolio and gain a competitive edge is contributing to the market growth. Other factors, such as rising healthcare expenditure, a growing number of clinical trials, easy availability of favorable reimbursement policies, and significant advancements in companion diagnostics, are presenting remunerative growth opportunities for the market. Looking forward, the market value is projected to reach US$ 327.8 Billion by 2028, expanding at a CAGR of 8.9% during 2023-2028.
- On the basis of the type, the market has been segregated into monoclonal antibodies, vaccines, interferons alpha and beta, and interleukins.
- Based on the therapy area, the market is categorized into cancer, autoimmune and inflammatory diseases, infectious diseases, and others.
- On the basis of the end user, the market has been classified into hospitals, clinics, and others.
- Region-wise, the market has been segmented into North America (the United States and Canada), Asia-Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others), Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others), Latin America (Brazil, Mexico, and others), and Middle East and Africa.
- The competitive landscape of the market has also been examined, with some of the key players being AstraZeneca plc, Bayer AG, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, F. Hoffmann-La Roche AG, GSK plc, Merck & Co. Inc., Pfizer Inc. and Sanofi S.A.
|Base Year of the Analysis
||Type, Therapy Area, End User, Region
|| Asia Pacific, Europe, North America, Latin America, Middle East and Africa
||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico
||AstraZeneca plc, Bayer AG, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, F. Hoffmann-La Roche AG, GSK plc, Merck & Co. Inc., Pfizer Inc. and Sanofi S.A.
||10% Free Customization
|Report Price and Purchase Option
||Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499
|Post-Sale Analyst Support
||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
30 N A
Tel No:(D) +91 120 433 0800
Americas:- +1 631 791 1145 | Africa and Europe :- +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800